Want to see SE:ENZY full AI Analyst Report?

Enzymatica AB (ENZY) Price & Analysis

0 Followers

ENZY Stock Chart & Stats

kr2.00

-kr0.34(-10.43%)

At close: Mar 06 4:00 PM EST

kr2.00

-kr0.34(-10.43%)

Day’s Range― - ―

52-Week Rangekr1.60 - kr3.40

Previous CloseN/A

Volume634.97K

Average Volume (3M)93.66K

Market Cap

kr450.27M

Enterprise Valuekr583.59

Total Cash (Recent Filing)kr13.14M

Total Debt (Recent Filing)kr14.17M

Price to Earnings (P/E)―

Beta0.08

Next Earnings

Oct 29, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.19

Shares Outstanding242,735,100

10 Day Avg. Volume44,136

30 Day Avg. Volume93,658

Financial Highlights & Ratios

PEG Ratio0.36

Price to Book (P/B)3.71

Price to Sales (P/S)8.56

P/FCF Ratio-11.19

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.3

Revenue Forecast (FY)kr109.00M

Bulls Say, Bears Say

Bulls Say

Gross Margin StrengthA ~59% TTM gross margin indicates strong product-level economics in the core consumer healthcare business. Durable gross profitability gives the company room to absorb SG&A and invest in distribution or marketing, improving the path to operating leverage if operating expenses stabilize.

Low Financial LeverageExtremely low debt levels materially reduce liquidity and refinancing risk, preserving flexibility to raise capital or endure cyclical slowdowns. This structural conservatism supports strategic options and lowers insolvency risk while the company works to stabilize cash flow.

Established Product And DistributionColdZyme's positioning as an established mouth/throat spray with pharmacy, retail and e-commerce distribution across markets supports recurring consumer demand and scalable retail placement. This distribution footprint underpins steady revenue potential as market expansion continues.

Bears Say

Persistent Negative Operating Cash FlowConsistent negative operating cash flow shows the business is not yet self-financing and depends on external funding or equity to continue. Over months this reduces runway, constrains reinvestment in growth initiatives, and increases dependency on capital markets or dilutive financing.

Deep Operating And Net LossesVery large negative operating and net margins indicate structural cost or scale issues: despite solid gross margin, fixed or operating expenses remain outsized. Sustained losses hinder ability to reinvest, deter partners, and make achieving sustainable profitability a multi-quarter structural challenge.

Eroding Equity And Negative ROEMaterial declines in equity and a ~-37% ROE reflect continued loss absorption by shareholders. Over time this weakens the balance sheet cushion, raises the prospect of future dilution or higher-cost capital, and limits the firm's ability to pursue larger strategic investments without external support.

ENZY FAQ

What was Enzymatica AB’s price range in the past 12 months?

Enzymatica AB lowest stock price was kr1.60 and its highest was kr3.40 in the past 12 months.

What is Enzymatica AB’s market cap?

Enzymatica AB’s market cap is kr450.27M.

When is Enzymatica AB’s upcoming earnings report date?

Enzymatica AB’s upcoming earnings report date is Oct 29, 2026 which is in 85 days.

How were Enzymatica AB’s earnings last quarter?

Enzymatica AB released its earnings results on Jul 16, 2026. The company reported -kr0.053 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.053.

Is Enzymatica AB overvalued?

According to Wall Street analysts Enzymatica AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Enzymatica AB pay dividends?

Enzymatica AB does not currently pay dividends.

What is Enzymatica AB’s EPS estimate?

Enzymatica AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Enzymatica AB have?

Enzymatica AB has 242,735,100 shares outstanding.

What happened to Enzymatica AB’s price movement after its last earnings report?

Enzymatica AB reported an EPS of -kr0.053 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.034%.

Which hedge fund is a major shareholder of Enzymatica AB?

Currently, no hedge funds are holding shares in SE:ENZY

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Enzymatica AB

Enzymatica AB, a life science company headquartered in Lund, Sweden, focuses on the development and sale of medical devices for infection-related illnesses. Founded in 2007, its primary offering is the ColdZyme mouth spray, designed to help prevent and reduce the duration of the common cold. The company also produces various enzyme formulations. This mouth spray is distributed across several European markets under different brand names: ViruProtect in Denmark, STADAProtect in Germany, Psysiomer Stop Virus in France, and Zerinol Virus Defense in Italy.